Compare Stocks: IONS, ROIV, BNTX, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$88.20 -2.2%	$99.10	$79.52 ▼ $124.00	$22.30B	1.25	1.09 million shs	388,536 shs
IONS Ionis Pharmaceuticals	$43.04 -2.5%	$52.03	$42.08 ▼ $86.74	$7.15B	0.38	2.65 million shs	515,759 shs
ROIV Roivant Sciences	$33.37 -2.0%	$36.66	$16.88 ▼ $42.50	$24.10B	1.1	6.36 million shs	1.45 million shs
UTHR United Therapeutics	$537.25 -0.8%	$513.75	$409.07 ▼ $609.35	$23.02B	0.49	555,203 shs	266,041 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.74%	-2.02%	-6.71%	-1.40%	-13.55%
IONS Ionis Pharmaceuticals	+3.33%	+1.89%	-6.62%	-18.88%	-39.05%
ROIV Roivant Sciences	+1.25%	-0.50%	-13.82%	-1.36%	+100.35%
UTHR United Therapeutics	+0.27%	+1.64%	+8.23%	+1.09%	+25.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$88.20 -2.2%	$99.10	$79.52 ▼ $124.00	$22.30B	1.25	1.09 million shs	388,536 shs
IONS Ionis Pharmaceuticals	$43.04 -2.5%	$52.03	$42.08 ▼ $86.74	$7.15B	0.38	2.65 million shs	515,759 shs
ROIV Roivant Sciences	$33.37 -2.0%	$36.66	$16.88 ▼ $42.50	$24.10B	1.1	6.36 million shs	1.45 million shs
UTHR United Therapeutics	$537.25 -0.8%	$513.75	$409.07 ▼ $609.35	$23.02B	0.49	555,203 shs	266,041 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.74%	-2.02%	-6.71%	-1.40%	-13.55%
IONS Ionis Pharmaceuticals	+3.33%	+1.89%	-6.62%	-18.88%	-39.05%
ROIV Roivant Sciences	+1.25%	-0.50%	-13.82%	-1.36%	+100.35%
UTHR United Therapeutics	+0.27%	+1.64%	+8.23%	+1.09%	+25.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.65	Moderate Buy	$125.44	42.22% Upside
IONS Ionis Pharmaceuticals	2.74	Moderate Buy	$89.14	107.14% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	36.78% Upside
UTHR United Therapeutics	2.71	Moderate Buy	$642.69	19.63% Upside

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	IONS Ionis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	UTHR United Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$368.00
10/15/2026	IONS Ionis Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$46.00 ➝ $88.00
10/14/2026	UTHR United Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$728.00
10/14/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$136.00 ➝ $132.00
10/12/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	ROIV Roivant Sciences	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Peer Perform
10/8/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$677.00 ➝ $708.00
10/8/2026	BNTX BioNTech	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold
10/7/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$115.00 ➝ $114.00
10/7/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$515.00 ➝ $566.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	6.87	$1.33 per share	66.41	$96.59 per share	0.91
IONS Ionis Pharmaceuticals	$874.09M	8.18	N/A	N/A	$3.02 per share	14.25
ROIV Roivant Sciences	$7.53M	3,199.72	N/A	N/A	$7.35 per share	4.54
UTHR United Therapeutics	$3.18B	7.24	$32.82 per share	16.37	$164.81 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	19.20	17.72	3.86	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest IONS, ROIV, BNTX, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.41	N/A	N/A	N/A	$3.74 million	N/A
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$183.31 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.21	N/A	N/A	N/A	$784.57 million	N/A
11/3/2026	Q3 2026	BNTX BioNTech	$0.8940	N/A	N/A	N/A	$1.20 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
IONS Ionis Pharmaceuticals	93.86%
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
IONS Ionis Pharmaceuticals	1.81%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

IONS, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR) Financial Analysis

October 16 at 4:46 AM | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

October 15 at 5:07 PM | marketbeat.com

United Therapeutics (UTHR) Settles Litigation And Resets Pulmonary Hypertension Competition

October 15 at 11:51 AM | finance.yahoo.com

Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement?

October 15 at 6:51 AM | uk.finance.yahoo.com

United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement

October 15 at 6:51 AM | finance.yahoo.com

What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring

October 14 at 4:51 PM | barchart.com

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

October 14 at 2:41 PM | zacks.com

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

October 14 at 1:16 PM | proactiveinvestors.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | zacks.com

United Therapeutics Corp. (UTHR) PT Raised to $728 at Jefferies

October 14 at 12:40 PM | streetinsider.com

LQDA stock rockets 40% today – BTIG calls United Therapeutics settlement better than best-case scenario

October 14 at 12:40 PM | msn.com

Liquidia adds over 30% on United Thera. settlement; BTIG upgrades

October 14 at 12:40 PM | seekingalpha.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | finance.yahoo.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:30 AM | 247wallst.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:05 AM | 247wallst.com

Liquidia shares jump as United Therapeutics settlement clears major YUTREPIA overhang

October 14 at 10:51 AM | quiverquant.comQ

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

October 14 at 9:56 AM | zacks.com

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

October 14 at 8:57 AM | barrons.com

Liquidia Settles Bitter Fight With United Therapeutics

October 14 at 8:30 AM | benzinga.com

United Therapeutics Reaches Major Pulmonary Hypertension Settlement

October 14 at 7:51 AM | tipranks.com

Liquidia Reaches Global Patent Settlement, Refines Financing

October 14 at 6:30 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

$88.20 -2.00 (-2.22%)

As of 12:50 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Ionis Pharmaceuticals NASDAQ:IONS

$43.04 -1.09 (-2.46%)

As of 12:50 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Roivant Sciences NASDAQ:ROIV

$33.36 -0.68 (-1.98%)

As of 12:50 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$537.25 -4.26 (-0.79%)

As of 12:50 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools